177 related articles for article (PubMed ID: 36498917)
21. Soluble Aβ aggregates can inhibit prion propagation.
Sarell CJ; Quarterman E; Yip DC; Terry C; Nicoll AJ; Wadsworth JDF; Farrow MA; Walsh DM; Collinge J
Open Biol; 2017 Nov; 7(11):. PubMed ID: 29142106
[TBL] [Abstract][Full Text] [Related]
22. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
23. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.
Nygaard HB; Strittmatter SM
Arch Neurol; 2009 Nov; 66(11):1325-8. PubMed ID: 19901162
[TBL] [Abstract][Full Text] [Related]
24. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues.
Chen S; Yadav SP; Surewicz WK
J Biol Chem; 2010 Aug; 285(34):26377-83. PubMed ID: 20576610
[TBL] [Abstract][Full Text] [Related]
25. Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation.
Glaves JP; Ladner-Keay CL; Bjorndahl TC; Wishart DS; Sykes BD
Biochim Biophys Acta Proteins Proteom; 2018 Sep; 1866(9):982-988. PubMed ID: 29935976
[TBL] [Abstract][Full Text] [Related]
26. The association between prion proteins and Aβ₁₋₄₂ oligomers in cytotoxicity and apoptosis.
Hyeon JW; Kim SY; Park JS; Choi BY; Lee SM; Ju YR; An SS; Kim CK
Biochem Biophys Res Commun; 2012 Jul; 424(2):214-20. PubMed ID: 22743555
[TBL] [Abstract][Full Text] [Related]
27. Preferential Recruitment of Conformationally Distinct Amyloid-β Oligomers by the Intrinsically Disordered Region of the Human Prion Protein.
Madhu P; Mukhopadhyay S
ACS Chem Neurosci; 2020 Jan; 11(1):86-98. PubMed ID: 31808343
[TBL] [Abstract][Full Text] [Related]
28. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
29. The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers.
Younan ND; Sarell CJ; Davies P; Brown DR; Viles JH
FASEB J; 2013 May; 27(5):1847-58. PubMed ID: 23335053
[TBL] [Abstract][Full Text] [Related]
30. Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models.
Kostylev MA; Kaufman AC; Nygaard HB; Patel P; Haas LT; Gunther EC; Vortmeyer A; Strittmatter SM
J Biol Chem; 2015 Jul; 290(28):17415-38. PubMed ID: 26018073
[TBL] [Abstract][Full Text] [Related]
31. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Um JW; Strittmatter SM
Prion; 2013; 7(1):37-41. PubMed ID: 22987042
[TBL] [Abstract][Full Text] [Related]
32. Soluble Prion Peptide 107-120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease.
Rezvani Boroujeni E; Hosseini SM; Fani G; Cecchi C; Chiti F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019683
[TBL] [Abstract][Full Text] [Related]
33. Peptide aptamer targeting Aβ-PrP-Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model.
Ali T; Klein AN; Vu A; Arifin MI; Hannaoui S; Gilch S
Cell Mol Life Sci; 2023 May; 80(6):139. PubMed ID: 37149826
[TBL] [Abstract][Full Text] [Related]
34. Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a
Younan ND; Chen KF; Rose RS; Crowther DC; Viles JH
J Biol Chem; 2018 Aug; 293(34):13090-13099. PubMed ID: 29887525
[TBL] [Abstract][Full Text] [Related]
35. Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures.
Bate C; Williams A
Neurobiol Dis; 2018 Mar; 111():48-58. PubMed ID: 29272738
[TBL] [Abstract][Full Text] [Related]
36. Amyloid-beta oligomers increase the localization of prion protein at the cell surface.
Caetano FA; Beraldo FH; Hajj GN; Guimaraes AL; Jürgensen S; Wasilewska-Sampaio AP; Hirata PH; Souza I; Machado CF; Wong DY; De Felice FG; Ferreira ST; Prado VF; Rylett RJ; Martins VR; Prado MA
J Neurochem; 2011 May; 117(3):538-53. PubMed ID: 21352228
[TBL] [Abstract][Full Text] [Related]
37. Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.
Gunther EC; Strittmatter SM
J Mol Med (Berl); 2010 Apr; 88(4):331-8. PubMed ID: 19960174
[TBL] [Abstract][Full Text] [Related]
38. PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.
Mengel D; Hong W; Corbett GT; Liu W; DeSousa A; Solforosi L; Fang C; Frosch MP; Collinge J; Harris DA; Walsh DM
Brain Res; 2019 May; 1710():125-135. PubMed ID: 30593771
[TBL] [Abstract][Full Text] [Related]
39. Prion protein and Alzheimer disease.
Kellett KA; Hooper NM
Prion; 2009; 3(4):190-4. PubMed ID: 19887909
[TBL] [Abstract][Full Text] [Related]
40. The pathogenesis of soluble PrP fragments containing Aβ binding sites.
Li B
Virus Res; 2016 Jan; 211():194-8. PubMed ID: 26528810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
